XTORO® (finafloxacin otic suspension), approved by the FDA, is a quinolone antimicrobial indicated for the treatment of acute otitis externa (AOE) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus. See full prescribing information here.
XTORO® is currently unavailable while updates to the product are under regulatory review. For more information, please contact our Medical Affairs team here.